IDEAYA Biosciences Inc

For the period ended Dec 31, 2024. Filed Feb 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 18, 2025

IDYA$32.03+2.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(in thousands, except share amounts)

Accumulated
Additional · Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income (Loss) · Deficit · Equity
Balances as of December 31, 2021	38,533,045	$4	$478,970	$(712)	$(176,748)		$301,514
Issuance of common stock upon follow-on public offering, net of issuance costs	8,761,905	1	86,080	—	—		86,081
Issuance of common stock related to at-the-market offering program, net of issuance costs	601,844	—	8,842	—	—		8,842
Issuance of common stock upon exercise of stock options	214,643	—	1,448	—	—		1,448
Employee stock purchase plan (ESPP) purchase	81,742	—	755	—	—		755
Stock-based compensation	—	—	11,629	—	—		11,629
Other comprehensive loss	—	—	—	(2,159)	—		(2,159)
Net loss	—	—	—	—	(58,655)		(58,655)
Balances as of December 31, 2022	48,193,179	5	587,724	(2,871)	(235,403)		349,455
Issuance of common stock upon follow-on public offering, net of issuance costs	14,655,993	2	281,120	—	—		281,122
Issuance of pre-funded warrants for the purchase of common stock	—	—	42,182	—	—		42,182
Issuance of common stock related to at-the-market offering program, net of issuance costs	1,188,705	—	28,598	—	—		28,598
Issuance of common stock upon exercise of stock options	931,012	—	9,559	—	—		9,559
Employee stock purchase plan (ESPP) purchase	70,480	—	1,213	—	—		1,213
Stock-based compensation	—	—	18,489	—	—		18,489
Other comprehensive gain	—	—	—	3,433	—		3,433
Net loss	—	—	—	—	(112,961)		(112,961)
Balances as of December 31, 2023	65,039,369	7	968,885	562	(348,364)		621,090
Issuance of common stock upon follow-on public offering, net of issuance costs	8,355,714	1	274,349			274,350
Issuance of pre-funded warrants for the purchase of common stock	—	—	9,400	—	—		9,400
Exercise of pre-funded warrants	1,749,993
Issuance of common stock related to at-the-market offering program, net of issuance costs	10,182,382	1	379,865	—	—		379,866
Issuance of common stock upon exercise of stock options	1,118,695	—	12,483	—	—		12,483
Employee stock purchase plan (ESPP) purchase	57,356	—	1,439	—	—		1,439
Stock-based compensation	—	—	34,746	—	—		34,746
Other comprehensive gain	—	—	—	250	—		250
Net loss	—	—	—	—	(274,477)		(274,477)
Balances as of December 31, 2024	86,503,509	$9	$1,681,167	$812	$(622,841)		$1,059,147

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.